Plus Therapeutics (NASDAQ:PSTV) Announces Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:PSTV) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16), Zacks reports. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.19 million.

Plus Therapeutics Price Performance

NASDAQ:PSTV opened at $1.16 on Friday. Plus Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.67. The firm has a market capitalization of $6.84 million, a PE ratio of -0.46 and a beta of 0.73. The business’s fifty day moving average price is $1.11 and its 200 day moving average price is $1.24.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PSTV. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Plus Therapeutics in a research note on Friday. Ascendiant Capital Markets cut their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Finally, HC Wainwright decreased their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.